MDACC Study No:2006-0709 ( NCT No: NCT00555399)
Title:Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults with Recurrent Glioblastoma Multiforme
Principal Investigator:Marta Penas-Prado
Treatment Agent:Isotretinoin; Temozolomide; Vorinostat
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest safe dose of
vorinostat (SAHA) when given with Accutane (isotretinoin) and temozolomide to
patients with malignant gliomas. The safety and effectiveness of this drug
combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I/Phase II
Treatment Agents:Isotretinoin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None
Supported By:N/A
Return Visit:Every 4 weeks for the first 2 cycles, then every 8 weeks.
Home Care:Vorinostat, temozolomide and isotretinoin are oral drugs that may be taken at

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marta Penas-Prado
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults